SOPHiA GENETICS (NASDAQ:SOPH) Issues Earnings Results

SOPHiA GENETICS (NASDAQ:SOPH) posted its quarterly earnings results on Tuesday. The company reported ($0.23) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.23), Zacks reports. SOPHiA GENETICS had a negative return on equity of 55.06% and a negative net margin of 110.71%. SOPHiA GENETICS updated its FY 2025 guidance to EPS.

SOPHiA GENETICS Price Performance

Shares of NASDAQ:SOPH opened at $3.57 on Tuesday. SOPHiA GENETICS has a 12 month low of $2.70 and a 12 month high of $7.37. The stock has a market cap of $233.39 million, a price-to-earnings ratio of -3.28 and a beta of 1.03. The stock’s 50 day moving average price is $3.58 and its 200 day moving average price is $3.56. The company has a debt-to-equity ratio of 0.12, a current ratio of 3.80 and a quick ratio of 3.59.

Analysts Set New Price Targets

Separately, Craig Hallum began coverage on SOPHiA GENETICS in a research note on Wednesday, December 18th. They issued a “buy” rating and a $11.00 target price on the stock. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $7.40.

About SOPHiA GENETICS

SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific.